Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01313117 · ClinicalTrials.gov registry record · Phase 1
Alpha-lipoic Acid in Patients at Risk for Paclitaxel Induced Neuropathy
A Phase 1 study, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT01313117 is a Phase 1 study that has completed, run by Northwestern University. The registered enrollment target is 9 participants.
The verdict
NCT01313117, a Phase 1 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This study is being done because peripheral neuropathy, a condition that interrupts sensation in your limbs, is a common side effect of paclitaxel. There is some evidence that alpha lipoic acid (ALA), an antioxidant compound, protects neurons after exposure to paclitaxel. The purpose of this study is to assess the safety and tolerability of ALA and to find the best dose of ALA in patients that receive chemotherapy.
Interventions
- DRUG Alpha lipoic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2012-02 |
| Est. Completion | 2014-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01313117
The ClinicalTrials.gov registry entry for NCT01313117 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Alpha lipoic acid is the first listed.
NCT01313117 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01313117 about?
NCT01313117 is a clinical study titled "Alpha-lipoic Acid in Patients at Risk for Paclitaxel Induced Neuropathy". This study is being done because peripheral neuropathy, a condition that interrupts sensation in your limbs, is a common side effect of paclitaxel. There is some evidence that alpha lipoic acid (ALA), an antioxidant compound, protects neurons after exposure to paclitaxel. The purpose of this study i...
What is the current status of trial NCT01313117?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2012-02. Estimated completion is 2014-01.
What interventions are being tested in trial NCT01313117?
The interventions under investigation include: Alpha lipoic acid (DRUG).
Who is sponsoring clinical trial NCT01313117?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.